Lung Cancer Special Issue (2)

Investigational Drug Shows Promise in Patients with RET-Altered Cancers

November 19, 2019

Pipeline

Patients with RET-fusion-positive non-small cell lung cancer (NSCLC) had a high response to LOXO-292 (selpercatinib), according to findings from the largest clinical trial of patients with RET-altered cancers.

x